Paxlovid recipients were at significantly lower risk for all-cause hospitalization than those given molnupiravir.
Paxlovid may better cut risk of severe COVID outcomes in asthma patients than molnupiravir
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- COVID 2024-25 vaccines 33% protective against emergency room or urgent care visits, data reveal
- US flu season shows signs of peak
- Hospitalized COVID patients at higher risk for organ-related death, readmission for 2.5 years, data suggest
- Liberals’, conservatives’ trust in US government’s use of digital health data diverged during COVID